E-DA Hospital
Kaohsiung City, 82445, Taiwan
Location status: Recruiting
NCT Number: NCT05818072
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.
Interested in participating?
Request Info20 year and older
All sexes
Interventional
Not applicable
Kaohsiung City, 82445, Taiwan
Location status: Recruiting
Barrett's esophagus (BE) is premalignant lesion for esophageal adenocarcinoma (EAC) and defined as the distal esophageal squamous epithelium replaced by columnar epithelium with histologic confirmation of intestinal metaplasia (IM). The accurate prevalence of BE is difficult to assess because part of people with BE are asymptomatic. However, the prevalence of gastroesophageal reflux disease (GERD) which is the main factor associated with BE has increased almost 50% during the last 20 years. Meanwhile, the general population prevalence of BE is estimated to increase to 3-10% in Western countries. The systematic review and meta-analysis also reported an upward trend in prevalence of BE in Asian countries. BE is an important heathy issue to investigate in either Western or Asian countries.
The annual rate of developing esophageal adenocarcinoma is around 0.2% to 0.5% in patients with BE. However, the annual adenocarcinoma progression risk is different between the non-dysplastic Barrett's esophagus (NDBE), BE with low-grade dysplasia (LGD) and high-grade dysplasia (HGD). The annual incidence of esophageal adenocarcinoma is 0.33%, 0.54% and 6.58% in patients with NDBE, BE with LGD and HGD, respectively. Among patients with NDBE, patients with short segment BE (SSBE) have the lower rate of progression to EAC than those who with long segment BE (LSBE) (0.07% vs 0.25%). Therefore, endoscopic surveillance of patients with BE is recommended by clinical practice guideline.
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of BE. According to the Seattle protocol which has been widely recommended by clinical practice guidelines, biopsy specimens should be obtained every one cm to two cm interval across the four quadrants of the columnar epithelium of esophagus. Fewer endoscopists adhered to this protocol in clinical practice because of its laboriousness and time consumption. Most of patients with BE were categorized as SSBE and SSBE seems to be more prevalent in Asian populations. As the report of previous study which reviewed the general prevalence of BE in Western and Asian general populations, the ratio of SSBE to LSBE was ranging from 1.8 to 17.4 in the Western countries and 1.7 to 103 in the Asian countries. It's more difficult to adhere to the protocol in patients with SSBE.
However, the optimal biopsy numbers and their yield rates of IM and dysplasia are still uncertain, especially in Asia. The investigators aimed to assess the biopsy numbers and yield rates of IM and dysplasia in patients with columnar-lined esophagus (CLE) to determine the optimal biopsy protocol.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
To do one biopsy at the proximal part of the longest columnar-lined esophagus.
To do three biopsy at the proximal, middle and distal part of the longest columnar-lined esophagus.
To do 4-quadrant biopsy every 1-2 cm at the esophagogastric junction. Seattle protocol has been considered as the gold standard biopsy protocol for patients with suspected Barrett's Esophagus.
The participants will receive meticulous endoscopic examination with narrow-band imaging.
Time frame: Up to 7 days histologic confirmation
Defined as the proportion of histologic confirmation of goblet cells
Time frame: Up to 7 days histologic confirmation
Defined as the proportion of histologic confirmation of columnar-lined epithelium with dysplasia
Time frame: From the date of procedure until any events, assessed up to 2 weeks
Including bleeding and perforation
Time frame: From forcep insertion to biopsy complete, assessed up to 1 minutes
Defined as from forcep insertion to biopsy complete
Contact information is provided by the study sponsor or research team.
Wen-Lun Wang, Ph.D
CONTACT
886-7-6150011 ext. 251346
Ying-Nan Tsai, M.D
CONTACT
886-7-6150011 ext. 252294
E-DA Hospital
Other
The Prevalence, Risk Factors and Optimal Biopsy Protocol of Barrett's Esophagus in Taiwan - A Prospective Randomized Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01787864
Barrett Esophagus, Barrett's Esophagus
Chapel Hill, North Carolina, United States
View Trial DetailsNCT02075905
Adenocarcinoma Of Esophagus, Barrett Esophagus
Chapel Hill, North Carolina, United States
View Trial DetailsNCT01373125
Barrett Esophagus, Barrett's Esophagus
Chapel Hill, North Carolina, United States
View Trial DetailsNCT01374074
Barrett Esophagus, Barrett's Esophagus
Chapel Hill, North Carolina, United States
View Trial Details